Zhu X, Kim J L, Newcomb J R, Rose P E, Stover D R, Toledo L M, Zhao H, Morgenstern K A
Kinetix Pharmaceuticals, Inc., Medford, MA 02155, USA.
Structure. 1999 Jun 15;7(6):651-61. doi: 10.1016/s0969-2126(99)80086-0.
The lymphocyte-specific kinase Lck is a member of the Src family of non-receptor tyrosine kinases. Lck catalyzes the initial phosphorylation of T-cell receptor components that is necessary for signal transduction and T-cell activation. On the basis of both biochemical and genetic studies, Lck is considered an attractive cell-specific target for the design of novel T-cell immunosuppressants. To date, the lack of detailed structural information on the mode of inhibitor binding to Lck has limited the discovery of novel Lck inhibitors.
We report here the high-resolution crystal structures of an activated Lck kinase domain in complex with three structurally distinct ATP-competitive inhibitors: AMP-PNP (a non-selective, non-hydrolyzable ATP analog); staurosporine (a potent but non-selective protein kinase inhibitor); and PP2 (a potent Src family selective protein tyrosine kinase inhibitor). Comparison of these structures reveals subtle but important structural changes at the ATP-binding site. Furthermore, PP2 is found to access a deep, hydrophobic pocket near the ATP-binding cleft of the enzyme; this binding pocket is not occupied by either AMP-PNP or staurosporine.
The potency of staurosporine against Lck derives in part from an induced movement of the glycine-rich loop of the enzyme upon binding of this ligand, which maximizes the van der Waals interactions present in the complex. In contrast, PP2 binds tightly and selectively to Lck and other Src family kinases by making additional contacts in a deep, hydrophobic pocket adjacent to the ATP-binding site; the amino acid composition of this pocket is unique to Src family kinases. The structures of these Lck complexes offer useful structural insights as they demonstrate that kinase selectivity can be achieved with small-molecule inhibitors that exploit subtle topological differences among protein kinases.
淋巴细胞特异性激酶Lck是非受体酪氨酸激酶Src家族的成员。Lck催化T细胞受体组分的初始磷酸化,这是信号转导和T细胞激活所必需的。基于生化和遗传学研究,Lck被认为是设计新型T细胞免疫抑制剂的一个有吸引力的细胞特异性靶点。迄今为止,缺乏关于抑制剂与Lck结合模式的详细结构信息限制了新型Lck抑制剂的发现。
我们在此报告活化的Lck激酶结构域与三种结构不同的ATP竞争性抑制剂形成复合物的高分辨率晶体结构:AMP-PNP(一种非选择性、不可水解的ATP类似物);星形孢菌素(一种强效但非选择性的蛋白激酶抑制剂);以及PP2(一种强效的Src家族选择性蛋白酪氨酸激酶抑制剂)。这些结构的比较揭示了ATP结合位点处细微但重要的结构变化。此外,发现PP2可进入该酶ATP结合裂隙附近的一个深的疏水口袋;该结合口袋未被AMP-PNP或星形孢菌素占据。
星形孢菌素对Lck的效力部分源于该配体结合后酶的富含甘氨酸环的诱导移动,这使复合物中存在的范德华相互作用最大化。相比之下,PP2通过在ATP结合位点附近的一个深的疏水口袋中形成额外接触而紧密且选择性地结合Lck和其他Src家族激酶;该口袋的氨基酸组成是Src家族激酶所特有的。这些Lck复合物的结构提供了有用的结构见解,因为它们表明可以用利用蛋白激酶之间细微拓扑差异的小分子抑制剂实现激酶选择性。